April 4, 2022

PLEASE DISTRIBUTE TO EMPLOYEES

TO: Department Heads
Departmental Human Resources Officers
County Personnel Officers

FROM: Derek Mizuno, Administrator

SUBJECT: 2022 Open Enrollment Informational Sessions (OE) for Active Employees

The Hawaii Employer-Union Health Benefits Trust Fund (EUTF) Active Employee Open Enrollment (OE) will be held this year from April 18 – May 13, 2022. The EUTF will be conducting all 2022 Active Employee OE informational sessions online again in place of in-person informational sessions.

To access the open enrollment virtual fair, go to eutf.hawaii.gov/learning-center and click on “Active Employee Open Enrollment Fair.” Employees will be able to view on-demand video presentations from the EUTF and each of the insurance carriers and attend an EUTF live webinar.

Attached is a flyer with the schedule of the Open Enrollment webinars.

We encourage you to visit the EUTF website for information regarding the 2022 Open Enrollment and your EUTF health plan options.

The following are the benefit plan changes:

HMSA Members
Benefit plan changes include:

1. Increased the Extended Care Facility benefit limit from 100 to 120 days per calendar year under the HMSA HMO plan effective July 1, 2022.

2. Added the Accordant Care Rare program which provides one-on-one, regular telephone consultations and coordinated care from registered nurses and other clinicians to patients managing certain rare, complex, and chronic conditions to all EUTF and HSTA VB active plans at no cost to the member effective January 1, 2022.

EUTF’s Mission: We care for the health and well-being of our beneficiaries by striving to provide quality benefit plans that are affordable, reliable, and meet their changing needs. We provide informed service that is excellent, courteous, and compassionate.
EUTF Prescription Drug Plan (administered by CVS/SilverScript)
Benefit plan changes effective January 1, 2022 (EUTF members only)
  3. Added the Drug Exclusion Plan Design program, which excludes targeted drugs with little or no clinical value.
  4. Added utilization management such as prior authorization, step-therapy, and/or quantity limits for the following drugs or classes: Acthar (treats infantile spasms); Afrezza (treats diabetes); Mupirocin (treats bacterial infections); Omega-3 fatty acids (treats hyperlipidemia); Palforzia (treats peanut allergies); products for migraine, neuralgia, psoriasis, and rosacea; and topical corticosteroids.

Effective October 14, 2021 (EUTF and HSTA VB members)
  5. Added prior authorization and quantity limit requirements for Ivermectin (treatment for parasitic infections).

Enclosures